Encorafenib, binimetinib clinical trials
4 indexed studies · 2 currently recruiting
- RecruitingPhase II
Assessing if stopping and starting standard of care medication for later stage melanoma can reduce the body's resistance to the treatment
This clinical trial tests a new way of taking standard medicines for advanced skin cancer (melanoma). Instead of taking pills every day, some patients take planned breaks guided by regular blood tests. Researchers want to see if pausing and restarting treatment stops cancer cells from becoming resistant, helping the medicine work longer.
For: Cutaneous melanomaUnited Kingdom · England · Scotland - RecruitingTherapeutic use (Phase IV)
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
This study looks at how well different treatments like surgery or radiotherapy work for people with a specific type of advanced melanoma. They are already taking two medicines, Encorafenib and Binimetinib, and researchers want to see if adding these other treatments helps them live longer without their cancer growing.
For: Unresectable or metastatic melanoma with a BRAF V600 mutation (inoperable stage III or metastatic stage IV)Germany - Active not recruiting
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
This study looks at how a melanoma treatment (encorafenib and binimetinib) works in everyday life for patients in the UK. We want to understand its effects and how it impacts quality of life, outside of a clinical trial.
For: Metastatic Melanoma, BRAF V600 Mutation PositiveUnited Kingdom - Active not recruitingPHASE2
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
This study looks at treating advanced melanoma with immunotherapy (nivolumab and ipilimumab) alone, or by starting with targeted therapy (encorafenib and binimetinib) for 12 weeks first. It aims to see if adding the targeted therapy first improves how long people live without their cancer growing.
For: Unresectable Stage III Melanoma · Stage IV MelanomaDenmark · Finland · France